Jul 2026· Journal of the American College of Cardiology· 0 citations· 162 references
Medicine
TL;DR
This review highlights well established indications, such as chronic heart failure with reduced ejection fraction and angina, while also examining recent studies that have questioned routine use in certain scenarios.
Abstract
Beta-blockers have long been a foundational pharmacotherapy in cardiovascular care across many disease conditions. However, the emergence of contemporary randomized trials and large population analyses has reshaped our understanding of their appropriate use. This review highlights well established indications, such as chronic heart failure with reduced ejection fraction and angina, while also examining recent studies that have questioned routine use in certain scenarios such as myocardial infarction in patients with preserved ejection fraction, stable coronary artery disease, heart failure with preserved ejection fraction, first-line antihypertensive therapy, and perioperative management. Evolving data suggest that benefits are more nuanced than previously recognized and must be individualized based on underlying pathology, ventricular function, and symptomatic burden. This article provides a practical, indication-focused framework and identifies areas where further evidence is needed to refine prescribing and deprescribing practices.
Current evidence suggests that beta-blockers can be prescribed based on comorbidity profiles rather than as HFpEF specific therapy, and well-designed randomized studies particularly those incorporating phenotype-based patient selection are needed to clarify the therapeutic role of beta-blockers.
S. Ray, Satyavir Yadav, Nitish Naik et al.· Indian Heart Journal· 0 citations
Overall, using a combination of these newer treatments may help people with heart failure whose heart still pumps normally or nearly normally feel better, improve their quality of life, and achieve better long-term health outcomes.
Craig J. Beavers, S. Greene· Heart Failure Reviews· 0 citations
BACKGROUND
While beta-blockers are effective at reducing mortality in certain cardiovascular diseases (CVD), their effectiveness in patients with chronic obstructive pulmonary disease (COPD) and CVD is uncertain, particularly with the concurrent use of long-acting β2-agonist bronchodilators (LABA).
RESEARCH QUESTION...
S. Suissa, S. Dell'Aniello, C. Renoux et al.· Chest· 0 citations
Obesity is a global epidemic, which, directly and indirectly, contributes to almost all cardiovascular diseases, including atherosclerotic cardiovascular disease, heart failure and atrial fibrillation. Reduction of weight is associated with substantial improvements in cardiometabolic risk factors, including blood press...
S. Ayton, D. Papamargaritis, Melanie J. Davies et al.· British Journal of Cardiolog...· 0 citations
Cardiovascular disease is the leading cause of morbidity and mortality in the elderly. Managing cardiovascular risk in this group is uniquely challenging due to physiological changes, multimorbidity, polypharmacy, and frailty, compounded by the under-representation of older adults in clinical trials Recent advances, in...
G. Dacquino, G. Galati, Luca Genovese et al.· European Journal of Preventi...· 0 citations
Hypertension remains the most prevalent modifiable cardiovascular risk factor worldwide, and continues to account for substantial morbidity, mortality, and health care burden despite established pharmacologic and lifestyle-based therapies. Poor long-term adherence, therapeutic inertia, polypharmacy, and persistent impl...
Shahzad Hassan, Iliana Samara Hurtado Rendon, Nikolaos Spilias et al.· American Journal of Hyperten...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
